Stock Analysis
Moderna, Inc. Common StockMRNA
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsHold30 analystsPrice is 91% of the way from the year's low to its high.
Cash covers 983% of debt · FY 2025.
PMP Verdict
Weak fundamentals, expensive
Strengths
- Financial Health100
Risks
- Valuation20
- Growth0
Weak fundamentals at a demanding price.
Market context
-7.8% today· Z 2.1σ· Profit-taking following a sharp recent rally to 52-week highs driven by cancer vaccine hype and Goldman's price target hike.
Bull Case
- ✓Altman Z 15.5 — safe-zone balance sheet
Why is MRNA moving?
TechnicalProfit-taking following a sharp recent rally to 52-week highs driven by cancer vaccine hype and Goldman's price target hike.
Profile
Strong financial health; growth, profitability, valuation, moat and earnings quality lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-1.4%)0/25
- P/S (38.6x)0/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (-43.0%)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-55.9%)0/25
- ROE (-36.4%)0/25
- Net margin (-141.4%)0/25
- Operating margin (-109.3%)0/25
- Financial Health100/100 · Strong
- Altman Z (15.49)25/25
- Current ratio (3.29)25/25
- Interest coverage (no interest expense)25/25
- Net cash / debt (Net cash)25/25
- Quality30/100 · Weak
- Piotroski F (3/9)5/25
- Beneish M (-2.88)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 423.0%)0/25
- Moat25/100 · Weak
- ROIC >12% years (2/7 yrs)0/25
- Median gross margin (63.6%)25/25
- FCF-positive years (3/8 yrs)0/25
- Worst-year net margin (worst -853.7%)0/25
Risk Flags
- ⚠Negative FCF margin (-0.6%) — burning cash
- ⚠SBC 20.7% of revenue — real dilution cost
- ⚠6 loss-making years in recent history
- ⚠Revenue shrinking 43.0%/yr
About Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. Show more
The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Headquarters: CAMBRIDGE, MA · Employees: 4,700 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF107.0xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-1.4%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -44.1%–26.1% · 64th pct
P/S (TTM)38.65xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 2.2x–42.4x · highest in history
EV/EBITDA107.6xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales42.3xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio9.95xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-4.57A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-55.9%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-36.4%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-26.9%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-141.4%D
Grade D: LowNet Income / Revenue
Operating Margin-109.3%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin23.4%D
Grade D: LowGross Profit / Revenue
FCF Margin-55.8%D
Grade D: LowFCF / Revenue
True FCF Margin-76.6%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR-43.0%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-7.2%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue20.7%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
100A+Altman Z-Score15.49A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio3.29xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.08xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage—
EBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT2.1xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.07xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt9.83xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
30DPiotroski F-Score3/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score-2.88A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability423.0%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue7.7%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.19xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Mock James M Filed | Mock James M | Option exercise | -1454 | |
Mock James M Filed | Mock James M | Tax withholding | -704 | |
Mock James M Filed | Mock James M | Option exercise | +1.5K | |
Hoge Stephen Filed | Hoge Stephen | Option exercise | -76452 | |
Hoge Stephen Filed | Hoge Stephen | SellOpen market sale | -40281 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Hoge Stephen Filed | Hoge Stephen | Option exercise | +76.5K | |
Hoge Stephen Filed | Hoge Stephen | Option exercise | -76453 | |
Hoge Stephen Filed | Hoge Stephen | SellOpen market sale | -40294 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
25EROIC >12% Years2/7 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)63.6%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years3/8 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-853.7%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$12.88
Cash & short-term investments per share (Finnhub)
Book Value / Share$16.94
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$590.00M
Total debt obligations (short + long term)
Cash & Equiv.$5.80B
Cash and short-term investments
Net Debt$-5.21BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$8.65B
Shareholders' equity (book value)
Asset / Liability3.35xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$86.11B
Current Market Capitalization
Beta1.18B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Moderna, Inc. Common Stock (MRNA)
MRNA is down 7.82% at the last close — Profit-taking following a sharp recent rally to 52-week highs driven by cancer vaccine hype and Goldman's price target hike.. Moderna, Inc. Common Stock meets only 3 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 15.49 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.88 suggests a low likelihood of earnings manipulation. Revenue has been contracting (CAGR ≈ -43%), which weighs on the growth outlook.
- Free-cash-flow margin is negative (-56%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Moderna, Inc. Common Stock posted a net loss in 6 of 8 available completed fiscal years (2018–2025).
- At a valuation score of 20/100, MRNA trades at a premium to its historical multiples.
See how MRNA ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all MRNA moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 16 | Regular | 214.30 | -9.39% | -2.24 |
| Oct 16 | After-hours | 215.69 | -8.80% | -2.12 |
| Oct 9 | Regular | 221.62 | +12.50% | 2.09 |
| Oct 9 | After-hours | 225.15 | +14.29% | 2.41 |
| Oct 6 | Regular | 188.25 | -7.36% | -2.18 |
Frequently Asked Questions about MRNA
What is the current Moderna, Inc. Common Stock (MRNA) stock price?
MRNA is trading at $218.01 at the last market close, down 7.82% on the session. PreMarketPrice tracks MRNA pre-market, intraday and after-hours prices.
Is MRNA stock a buy right now?
PreMarketPrice's quantitative model rates Moderna, Inc. Common Stock's financial health at 100/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is MRNA stock overvalued?
Moderna, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Moderna, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for MRNA. The Earnings section lists recent reports and updates as dates are announced.
What sector does Moderna, Inc. Common Stock operate in?
Moderna, Inc. Common Stock operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Moderna, Inc. Common Stock do?
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018.
About Moderna, Inc. Common Stock (MRNA) Stock
Moderna, Inc. Common Stock (MRNA) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Moderna, Inc. Common Stock is trading at $218.01, down 7.82% on the day with a market capitalization of $86.1 billion. The financial health score for MRNA is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for MRNA stock.
MRNA Stock Analysis & Key Metrics
On PreMarketPrice, you can track Moderna, Inc. Common Stock (MRNA) across multiple dimensions:
- Pre-market price & movement: Real-time MRNA stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for MRNA with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Moderna, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for MRNA.
- Sector peers: Compare MRNA against 6 other healthcare stocks on key financial metrics.
Is MRNA a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Moderna, Inc. Common Stock (MRNA) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Moderna, Inc. Common Stock (MRNA) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.